- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02416518
Genetic Exploration of the Molecular Basis of Malignancy in Adults (GEMMA)
April 1, 2019 updated by: Sanford Health
Genetic Exploration of the Molecular Basis of Malignancy in Adults.
Study Overview
Status
Completed
Conditions
Detailed Description
This protocol is not designed as a treatment protocol.
Patients enrolled on this study will be treated according to the treating physician's plan of care, independent of enrollment into the study.
Once enrolled, the physician may proceed with the appropriate plan of care during the period of specimen analysis if indicated.
Upon return of the results, therapy may or may not be altered based upon the patient's pathology, pertinent medical and treatment history, imaging studies, available clinical trials, and on the CLIA validated clinical molecular profiling results.
Regardless of the results, the patient will be offered a treatment selected on an empirical basis by the treating physician at the individual site.
All patients enrolled in the study will be followed for clinical outcome.
Clinical molecular profiling results will expire 14 weeks following the date the Foundation One report is received.
No investigational agents will be administered as part of this study.
However, patients may be referred to open clinical trials based on the results of profiling.
Patients referred for clinical trial may receive investigational agents under a separate clinical trial in accordance with the written protocol for which they are subsequently enrolled.
All anti-neoplastic drugs used while participating in this study, whether used on-label or off-label, will be administered to the patient by the route of administration published in the FDA approved package insert.
In addition, the dosing of the agent (including dose modifications) will be calculated based upon what is published in the FDA approved package insert.
Study Type
Observational
Enrollment (Actual)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Bemidji, Minnesota, United States, 56601
- Sanford Health
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Sanford Health
-
Fargo, North Dakota, United States, 57102
- Sanford Health
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57104
- Sanford Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult patients with metastatic, incurable cancer or cancer with no standard 1st-line systemic therapy that has shown prolonged survival
Description
Inclusion Criteria:
- Understand and provide written informed consent and HIPAA Authorization prior to initiation of any study-specific procedures.
- Have a life expectancy of >3 months.
- Have a diagnosis of metastatic, incurable cancer and have progressed on at least one line of systemic therapy OR a cancer with no standard 1st-line systemic therapy shown to prolong survival (or where a clinical trial recommended as the 1st-line option). Patients do not have to be off-treatment when enrolled on this trial. However, please see section 6.4.8 regarding the required wash-out period before starting any FDA approved on-label or off-label treatment.
- Measurable disease (RECIST 1.1).
- Be ≥18 years of age.
- ECOG Performance status 0 or 1.
- In the opinion of the investigator, be medically suitable for and willing to undergo a biopsy or surgical procedure to obtain tissue as a part of routine care for their malignancy OR have adequate archival tissue from a previous biopsy, performed no more than 14 weeks prior to enrollment, available for profiling.
- Have adequate organ and bone marrow function as defined below: Bone marrow: absolute neutrophil count (ANC) ≥ 1.5 x 109/L; hemoglobin ≥ 9 g/dL; platelets >100 x 109/L Renal: creatinine clearance ≥ 60 mL/min (calculated according to Cockcroft and Gault formula) or creatinine ≤ 1.5 mg/dL Hepatic: bilirubin ≤ 2.5 x the upper limit of normal (ULN); aspartate transaminases (AST/SGOT); alanine transaminases (ALT/SGPT) ≤ 2.5 x ULN (or ≤ 5 x ULN if due to underlying liver metastases)
- Female patients of childbearing potential must have a negative pregnancy test and agree to use at least two forms of contraception during the study and for at least one month after treatment discontinuation. For the purposes of this study, a female with child- bearing potential is defined as: any woman who meets the following criteria.
Has not undergone a hysterectomy or bilateral oophorectomy. Has not been naturally postmenopausal for at least 24 months (i.e. has had a menses at any time in the preceding 24 consecutive months).
- Male patients must use a form of barrier contraception that contains spermicide and is approved by the investigator / treating physician during the study and for at least one month after treatment discontinuation.
- No more than one prior screening attempt for SH GEMMA.
Exclusion Criteria:
- Have lesions that are not accessible to biopsy or not planned for biopsy as part of routine care OR if archival tissue will be used for profiling, an insufficient amount is available OR archival tissue was obtained ≥ 14 weeks prior to enrollment.
- Have diagnosis of a hematologic malignancy.
- Diagnosis of astrocytoma, glioblastoma multiforme, or any other primary brain cancer.
- Have concurrent uncontrolled malignancy.
- Have symptomatic CNS metastasis. Patients with a history of CNS metastases who have been treated with whole brain irradiation must be stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be either off steroids or on a stable dose of steroids for ≥ 2 weeks prior to enrollment.
- Have uncontrolled concurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmias, psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
- Have known HIV, HBV, HCV infection.
- Previous enrollment in the SH GEMMA study. Patients are allowed one prior screening attempt.
- Are pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility (proportion of patients with successful molecular profiling compared to the number of patients enrolled)
Time Frame: 12 months
|
Assess the feasibility of integrating genomic profiling in the adult oncology clinic within a community-based, multi-facility, health system.
Feasibility is defined as the proportion of patients with successful molecular profiling compared to the number of patients enrolled.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient and biopsy characteristics (including cancer type, biopsy type, and number of prior treatments)
Time Frame: 12 months
|
Determine patient and biopsy characteristics, including cancer type, biopsy type, and number of prior treatments
|
12 months
|
Molecular testing characteristics (include: the frequency at which molecular analysis yields a genetic alteration, frequency of actionable alterations, and time from biopsy to final report)
Time Frame: 12 months
|
Define molecular testing characteristics.This will include: the frequency at which molecular analysis yields a genetic alteration, frequency of actionable alterations, and time from biopsy to final report.
|
12 months
|
Molecular profiling influence
Time Frame: 12 months
|
Determine how often molecular profiling influences treatment decision.Treatment type implemented will be classified as: standard therapy per treating physician, FDA approved off-label influenced by molecular profiling, internal targeted agent clinical trial influenced by molecular profiling, or external targeted agent clinical trial influenced by molecular profiling.
|
12 months
|
Clinical outcome of genomic based therapy (response according to RECIST 1.1 response criteria)
Time Frame: At 16wks following initiation of treatment impacted by molecular profiling. After 16wks tumor assessments per routine practice/clinical trial protocol requirements, continued until progression/time of treatment discontinuation, whichever is later.
|
Determine the clinical outcome of genomic based therapy, as defined by response rate (according to RECIST 1.1 response criteria) the percent of patients with progression-free survival (PFS) at 4 months, and overall survival.
|
At 16wks following initiation of treatment impacted by molecular profiling. After 16wks tumor assessments per routine practice/clinical trial protocol requirements, continued until progression/time of treatment discontinuation, whichever is later.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Steven Powell, MD, Sanford Health
- Principal Investigator: Anu Gaba, MD, Sanford Health
- Principal Investigator: John Reynolds, MD, Sanford Health
- Principal Investigator: Jayan Nair, MD, Sanford Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Actual)
March 1, 2018
Study Completion (Actual)
December 1, 2018
Study Registration Dates
First Submitted
August 15, 2014
First Submitted That Met QC Criteria
April 14, 2015
First Posted (Estimate)
April 15, 2015
Study Record Updates
Last Update Posted (Actual)
April 2, 2019
Last Update Submitted That Met QC Criteria
April 1, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SH GEMMA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedUterine Neoplasms | Prostatic Neoplasms | Cervix Neoplasms | Bladder NeoplasmsCanada
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
N.N. Petrov National Medical Research Center of...Active, not recruitingColonic Neoplasms MalignantRussian Federation
-
Peking University First HospitalShengli Oilfield Hospital; The Second Affiliated Hospital of Baotou Medical...Enrolling by invitationRectal Neoplasms MalignantChina
-
Cancer Institute and Hospital, Chinese Academy...CompletedRectal Neoplasms MalignantChina
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States